This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsCanntab Therapeutics（PILL）株式概要カンタブ・セラピューティクス社は植物製薬会社であり、カナダで先進医薬品グレードのカンナビノイド製剤の研究開発に従事している。 詳細PILL ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析株式の流動性は非常に低い マイナスの株主資本 収益が 100 万ドル未満 ( CA$73K )意味のある時価総額がありません ( CA$195K )+1 さらなるリスクすべてのリスクチェックを見るPILL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW495,370 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG495,370 investors already sharing narrativesYour Fair ValueCA$Current PriceN/A該当なし内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-5m843k2016201920222025202620282031Revenue CA$73.5kEarnings CA$10.8kAdvancedSet Fair ValueView all narrativesCanntab Therapeutics Limited 競合他社Steep HillSymbol: CNSX:STPHMarket cap: CA$889.2kHempsana HoldingsSymbol: CNSX:HMPSMarket cap: CA$591.3kSugarBud Craft GrowersSymbol: TSXV:SUGR.HMarket cap: CA$718.6kClaritas PharmaceuticalsSymbol: TSXV:CLAS.HMarket cap: CA$944.7k価格と性能株価の高値、安値、推移の概要Canntab Therapeutics過去の株価現在の株価CA$052週高値CA$0.0252週安値CA$0.005ベータ1.431ヶ月の変化n/a3ヶ月変化n/a1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化n/a最新ニュースReported Earnings • Apr 29Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.011 loss in 3Q 2022)Third quarter 2023 results: CA$0.01 loss per share (improved from CA$0.011 loss in 3Q 2022). Net loss: CA$412.6k (loss narrowed 1.4% from 3Q 2022).Reported Earnings • Jan 27Second quarter 2023 earnings released: CA$0.026 loss per share (vs CA$0.033 loss in 2Q 2022)Second quarter 2023 results: CA$0.026 loss per share (improved from CA$0.033 loss in 2Q 2022). Revenue: CA$17.6k (down 90% from 2Q 2022). Net loss: CA$1.03m (loss narrowed 16% from 2Q 2022).Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Aug 03Canntab Therapeutics Limited Announces Chief Executive Office ChangesCanntab Therapeutics Limited announces that it has appointed Richard Goldstein, currently serving as Canntab's CFO, as interim CEO of Canntab, effective July 31, 2022. Mr. Goldstein replaces the outgoing CEO of the Board Larry Latowsky who stepped down to pursue other opportunities. Mr. Latowsky will continue to serve as an advisor to the board of directors of Canntab and oversee the direction and development of business with First Nations communities across Canada per agreements previously announced. The board of directors of Canntab has commenced a formal search for a permanent CEO. Further announcements will be made as and when appropriate.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Recent Insider Transactions • Feb 12Co-Founder recently bought CA$226k worth of stockOn the 10th of February, Richard Goldstein bought around 310k shares on-market at roughly CA$0.73 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$565k worth in shares.最新情報をもっと見るRecent updatesReported Earnings • Apr 29Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.011 loss in 3Q 2022)Third quarter 2023 results: CA$0.01 loss per share (improved from CA$0.011 loss in 3Q 2022). Net loss: CA$412.6k (loss narrowed 1.4% from 3Q 2022).Reported Earnings • Jan 27Second quarter 2023 earnings released: CA$0.026 loss per share (vs CA$0.033 loss in 2Q 2022)Second quarter 2023 results: CA$0.026 loss per share (improved from CA$0.033 loss in 2Q 2022). Revenue: CA$17.6k (down 90% from 2Q 2022). Net loss: CA$1.03m (loss narrowed 16% from 2Q 2022).Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Aug 03Canntab Therapeutics Limited Announces Chief Executive Office ChangesCanntab Therapeutics Limited announces that it has appointed Richard Goldstein, currently serving as Canntab's CFO, as interim CEO of Canntab, effective July 31, 2022. Mr. Goldstein replaces the outgoing CEO of the Board Larry Latowsky who stepped down to pursue other opportunities. Mr. Latowsky will continue to serve as an advisor to the board of directors of Canntab and oversee the direction and development of business with First Nations communities across Canada per agreements previously announced. The board of directors of Canntab has commenced a formal search for a permanent CEO. Further announcements will be made as and when appropriate.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Recent Insider Transactions • Feb 12Co-Founder recently bought CA$226k worth of stockOn the 10th of February, Richard Goldstein bought around 310k shares on-market at roughly CA$0.73 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$565k worth in shares.お知らせ • Feb 03Canntab Therapeutics Limited announced that it has received CAD 1.312 million in fundingCanntab Therapeutics Limited announced a non-brokered private placement of secured convertible debentures for gross proceeds of CAD 1,312,000 on February 1, 2022. The convertible debentures are convertible into common shares at a conversion price of CAD 0.70 per share, and will mature two years from the date of issuance. Beginning on the date that is four months and one day following the closing date of the transaction, the company will have the right to prepay or redeem a part or the entire principal amount of the convertible debentures plus any accrued and unpaid interest at any time by providing a minimum of 20 days and a maximum 60 days of redemption notice prior to the redemption date. The conversion price will be subject to customary adjustments in certain events. The company also has the right to force the conversion of all of the principal amount of the then outstanding convertible debentures at the conversion price upon giving the Debenture holders not less than 30 days advance written notice, should the volume weighted average trading price of the shares on the Canadian Securities Exchange be greater than CAD 1.05 per share for the preceding 15 consecutive trading days. The convertible debentures shall bear interest at a rate of 10% per annum from the closing date, paid upfront in cash for the initial six months, thereafter payable quarterly in cash on the last business day of each calendar quarter. Any accrued but unpaid interest is convertible into shares, at the option of the holder at the conversion price at any time following the closing date. The company has also issued one Share purchase warrants for each share underlying the convertible debenture purchased. The warrants are exercisable for a period of three years from issuance into shares of the company with each warrant entitling the holder thereof to acquire one share at an exercise price of CAD 0.90 per share. There were no broker warrants issued or commission paid in connection to the offering. All of the securities issued pursuant to the transaction are subject to a statutory hold period of four months and one day from the closing date of the transaction.お知らせ • Jan 22Canntab Therapeutics Limited Officially Launches its Online E-Commerce PlatformCanntab Therapeutics Limited announced the official launch of its online e-commerce platform. The E-Commerce platform and web site provides Canadians with an opportunity to source true medical THC and CBD in a pharmaceutical grade hard tablet. The Canntab tablet provides patients with many added benefits including ease of use, efficacy, exact dosage, and bioavailability. Canntab is now able to script patients directly online, take in existing or new prescriptions from Doctors or even share a prescription with another LP. Canntab and its patented formulations is the only provider THC and CBD in hard tablet in Canada. Since receiving a Medical Sales License from Health Canada on November 11, 2021, Canntab has been focused on the full commercialization of its brand and products. The recently announced OCS initial shipment and Australian 2nd shipment are just 2 examples of what is expected to be numerous developments in the very near future. In addition, affiliates across Canada like pharmacy groups, health and wellness practitioners, sleep and pain clinics and other medical professionals will now be able to recommend or prescribe product and be compensated for doing so.Recent Insider Transactions • Oct 03Co-Founder recently bought CA$95k worth of stockOn the 1st of October, Richard Goldstein bought around 135k shares on-market at roughly CA$0.70 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$339k worth in shares.Recent Insider Transactions Derivative • Jun 11Co-Founder exercised options to buy CA$310k worth of stock.On the 7th of June, Richard Goldstein exercised options to buy 320k shares at a strike price of around CA$0.75, costing a total of CA$240k. This transaction amounted to 65% of their direct individual holding at the time of the trade. Since December 2020, Richard's direct individual holding has increased from 39.19k shares to 464.59k. Company insiders have collectively bought CA$525k more than they sold, via options and on-market transactions, in the last 12 months.Recent Insider Transactions • May 08Co-Founder recently bought CA$60k worth of stockOn the 5th of May, Richard Goldstein bought around 60k shares on-market at roughly CA$1.00 per share. In the last 3 months, they made an even bigger purchase worth CA$100k. Richard has been a buyer over the last 12 months, purchasing a net total of CA$222k worth in shares.Recent Insider Transactions • Apr 28Co-Founder recently bought CA$100k worth of stockOn the 23rd of April, Richard Goldstein bought around 100k shares on-market at roughly CA$1.00 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$162k worth in shares.お知らせ • Apr 01Canntab Receives Export License Approval from Health CanadaCanntab Therapeutics Limited announced that Health Canada has granted the company an Export License.お知らせ • Mar 11Canntab Therapeutics Limited Receives $400K Purchase Order in AustraliaCanntab Therapeutics Limited announced that further to an announcement made on October 26, 2020, Canntab has now received an initial purchase order in the amount of $406,200 with its Australian partner, Cann Global Limited of Australia ("Cann Global"). The initial purchase order includes 6 sku's comprised of 2.5mg THC, 5mg THC, 12.5mg CBD, 25mg THC, and combined caplets (a hard coated tablet in the shape of a capsule) with 5mg THC/25mg CBD and 2.5mg THC/12.5mg CBD. Cann Global has already received its import license from the Australian Government Department of Health while Canntab is waiting for an Export License approval from Health Canada to fulfil and ship the order. The products ordered by Cann Global will be distributed throughout Australia to medical distributors, including Doctors, Pharmacies, and Hospitals. Canntab will update its shareholders as soon as its Export License has been approved.Is New 90 Day High Low • Feb 10New 90-day high: CA$0.95The company is up 36% from its price of CA$0.70 on 11 November 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 92% over the same period.Is New 90 Day High Low • Dec 09New 90-day high: CA$0.76The company is up 21% from its price of CA$0.63 on 09 September 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 53% over the same period.お知らせ • Dec 03Canntab Therapeutics Limited Begins Delivery of Tablets to MediPharmCanntab Therapeutics Limited announce that it has completed its first delivery of two (2) of a total of five (5) SKU's ordered by MediPharm Labs Corp. Further to Canntab's announcement dated June 2, 2020, the Company confirms that the total purchase order is approximately $1.3 Million. Canntab intends to complete and deliver the entire order by the end of 2020.お知らせ • Nov 18Canntab Therapeutics Limited Announces End of Supply and Distribution Agreements with ExactusCanntab Therapeutics Limited announced that Canntab and Exactus, Inc. have blends in hard pill form for therapeutic applications, announces that Canntab and Exactus, Inc. have mutually agreed to terminate the supply and distribution agreements previously announced on November 20, 2019, after determining that the regulatory requirements could not be completed on a timely basis. During a time of pandemic and closed borders, both companies decided it would be best to mutually terminate the agreements in place. However, both companies have expressed an interest in working together in the future, and intend to make a decision in that regard once circumstances surrounding the COVID-19 pandemic have improved.お知らせ • Nov 07Canntab Therapeutics Limited, Annual General Meeting, Jan 15, 2021Canntab Therapeutics Limited, Annual General Meeting, Jan 15, 2021.お知らせ • Oct 20Canntab Therapeutics Limited (CNSX:PILL) completed the acquisition of CMAX Assets of CMAX Technologies Inc.Canntab Therapeutics Limited (CNSX:PILL) entered into a binding asset purchase agreement to acquire CMAX Assets of CMAX Technologies Inc. for CAD 1.4 million on August 21, 2020. CMAX Assets includes certain cannabis-processing equipment and leasehold improvements located at 223 Riviera Drive, Markham, Ontario facility. The purchase price will be satisfied through the issuance of 1.9 million common shares. A deposit of 0.2 million Common Shares will be paid to CMAX within 14 days of the execution of the purchase agreement. On July 15, 2020, 200,000 common shares were issued to CMAX as a deposit on this transaction. The transaction is subject to customary closing conditions. The transaction has been approved by the independent Director of Canntab Therapeutics. Canntab Therapeutics Limited (CNSX:PILL) completed the acquisition of CMAX Assets of CMAX Technologies Inc. on October 19, 2020.お知らせ • Oct 01Canntab Therapeutics Limited Auditor Raises 'Going Concern' DoubtCanntab Therapeutics Limited filed its Annual on Sep 28, 2020 for the period ending May 31, 2020. In this report its auditor, Meyers Norris Penny LLP - MNP LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.Reported Earnings • Sep 30Full year earnings released - CA$0.10 loss per shareOver the last 12 months the company has reported total losses of CA$2.61m, with losses widening by 6.0% from the prior year.お知らせ • Aug 22Canntab Therapeutics Limited (CNSX:PILL) entered into a binding asset purchase agreement to acquire CMAX Assets of CMAX Technologies Inc. for CAD 1.4 million.Canntab Therapeutics Limited (CNSX:PILL) entered into a binding asset purchase agreement to acquire CMAX Assets of CMAX Technologies Inc. for CAD 1.4 million on August 21, 2020. CMAX Assets includes certain cannabis-processing equipment and leasehold improvements located at 223 Riviera Drive, Markham, Ontario facility. The purchase price will be satisfied through the issuance of 1.9 million common shares. A deposit of 0.2 million Common Shares will be paid to CMAX within 14 days of the execution of the purchase agreement. The transaction is subject to customary closing conditions. The transaction has been approved by the independent director of Canntab Therapeutics.お知らせ • Aug 20Canntab Therapeutics Limited Announces Appointment of Larry Latowsky as CEOCanntab Therapeutics Limited announced that it has appointed Larry Latowsky as CEO effective immediately. Originally appointed as an Advisor to the Company, it was mutually decided that Mr. Latowsky's extensive experience and connections in wholesale, retail and direct to consumer pharmaceutical industries would be an essential ingredient to the operations of the company and accordingly the board of directors decided to appoint Larry as CEO.株主還元PILLCA PharmaceuticalsCA 市場7Dn/a-2.2%0.2%1Yn/a32.9%27.9%株主還元を見る業界別リターン: PILLがCanadian Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: PILL Canadian市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is PILL's price volatile compared to industry and market?PILL volatilityPILL Average Weekly Movementn/aPharmaceuticals Industry Average Movement9.8%Market Average Movement9.5%10% most volatile stocks in CA Market16.3%10% least volatile stocks in CA Market3.6%安定した株価: PILL 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 過去 1 年間のPILLのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aRichard Goldsteincanntab.caCanntab Therapeutics Limitedは植物医薬品会社で、カナダで高度な医薬品グレードのカンナビノイド製剤の研究開発に従事している。徐放性カンナビノイド製剤やペレット、即時放出カンナビジオール製剤、改良放出多層カンナビノイド製剤、フラッシュメルトカンナビノイド製剤、二層カンナビノイド錠剤など、睡眠障害、心的外傷後ストレス障害、社会不安、依存症、関節炎、一般疼痛、疼痛管理、がん治療に伴う食欲減退、オピオイドやその他の鎮痛剤の依存症治療などの治療用の医薬品カンナビノイドの経口投与製剤を提供している。キャンタブ・セラピューティクス社はカナダのマーカムに本社を置いている。もっと見るCanntab Therapeutics Limited 基礎のまとめCanntab Therapeutics の収益と売上を時価総額と比較するとどうか。PILL 基礎統計学時価総額CA$194.55k収益（TTM）-CA$3.36m売上高(TTM)CA$73.48k0.0xP/Sレシオ0.0xPER（株価収益率PILL は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PILL 損益計算書（TTM）収益CA$73.48k売上原価CA$1.40m売上総利益-CA$1.33mその他の費用CA$2.03m収益-CA$3.36m直近の収益報告Feb 28, 2023次回決算日該当なし一株当たり利益（EPS）-0.086グロス・マージン-1,806.30%純利益率-4,566.80%有利子負債／自己資本比率-87.8%PILL の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/06/18 16:31終値2024/04/08 00:00収益2023/02/28年間収益2022/05/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Canntab Therapeutics Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Apr 29Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.011 loss in 3Q 2022)Third quarter 2023 results: CA$0.01 loss per share (improved from CA$0.011 loss in 3Q 2022). Net loss: CA$412.6k (loss narrowed 1.4% from 3Q 2022).
Reported Earnings • Jan 27Second quarter 2023 earnings released: CA$0.026 loss per share (vs CA$0.033 loss in 2Q 2022)Second quarter 2023 results: CA$0.026 loss per share (improved from CA$0.033 loss in 2Q 2022). Revenue: CA$17.6k (down 90% from 2Q 2022). Net loss: CA$1.03m (loss narrowed 16% from 2Q 2022).
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Aug 03Canntab Therapeutics Limited Announces Chief Executive Office ChangesCanntab Therapeutics Limited announces that it has appointed Richard Goldstein, currently serving as Canntab's CFO, as interim CEO of Canntab, effective July 31, 2022. Mr. Goldstein replaces the outgoing CEO of the Board Larry Latowsky who stepped down to pursue other opportunities. Mr. Latowsky will continue to serve as an advisor to the board of directors of Canntab and oversee the direction and development of business with First Nations communities across Canada per agreements previously announced. The board of directors of Canntab has commenced a formal search for a permanent CEO. Further announcements will be made as and when appropriate.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Recent Insider Transactions • Feb 12Co-Founder recently bought CA$226k worth of stockOn the 10th of February, Richard Goldstein bought around 310k shares on-market at roughly CA$0.73 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$565k worth in shares.
Reported Earnings • Apr 29Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.011 loss in 3Q 2022)Third quarter 2023 results: CA$0.01 loss per share (improved from CA$0.011 loss in 3Q 2022). Net loss: CA$412.6k (loss narrowed 1.4% from 3Q 2022).
Reported Earnings • Jan 27Second quarter 2023 earnings released: CA$0.026 loss per share (vs CA$0.033 loss in 2Q 2022)Second quarter 2023 results: CA$0.026 loss per share (improved from CA$0.033 loss in 2Q 2022). Revenue: CA$17.6k (down 90% from 2Q 2022). Net loss: CA$1.03m (loss narrowed 16% from 2Q 2022).
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Aug 03Canntab Therapeutics Limited Announces Chief Executive Office ChangesCanntab Therapeutics Limited announces that it has appointed Richard Goldstein, currently serving as Canntab's CFO, as interim CEO of Canntab, effective July 31, 2022. Mr. Goldstein replaces the outgoing CEO of the Board Larry Latowsky who stepped down to pursue other opportunities. Mr. Latowsky will continue to serve as an advisor to the board of directors of Canntab and oversee the direction and development of business with First Nations communities across Canada per agreements previously announced. The board of directors of Canntab has commenced a formal search for a permanent CEO. Further announcements will be made as and when appropriate.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Advisory Board Bob Woloschuk was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Recent Insider Transactions • Feb 12Co-Founder recently bought CA$226k worth of stockOn the 10th of February, Richard Goldstein bought around 310k shares on-market at roughly CA$0.73 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$565k worth in shares.
お知らせ • Feb 03Canntab Therapeutics Limited announced that it has received CAD 1.312 million in fundingCanntab Therapeutics Limited announced a non-brokered private placement of secured convertible debentures for gross proceeds of CAD 1,312,000 on February 1, 2022. The convertible debentures are convertible into common shares at a conversion price of CAD 0.70 per share, and will mature two years from the date of issuance. Beginning on the date that is four months and one day following the closing date of the transaction, the company will have the right to prepay or redeem a part or the entire principal amount of the convertible debentures plus any accrued and unpaid interest at any time by providing a minimum of 20 days and a maximum 60 days of redemption notice prior to the redemption date. The conversion price will be subject to customary adjustments in certain events. The company also has the right to force the conversion of all of the principal amount of the then outstanding convertible debentures at the conversion price upon giving the Debenture holders not less than 30 days advance written notice, should the volume weighted average trading price of the shares on the Canadian Securities Exchange be greater than CAD 1.05 per share for the preceding 15 consecutive trading days. The convertible debentures shall bear interest at a rate of 10% per annum from the closing date, paid upfront in cash for the initial six months, thereafter payable quarterly in cash on the last business day of each calendar quarter. Any accrued but unpaid interest is convertible into shares, at the option of the holder at the conversion price at any time following the closing date. The company has also issued one Share purchase warrants for each share underlying the convertible debenture purchased. The warrants are exercisable for a period of three years from issuance into shares of the company with each warrant entitling the holder thereof to acquire one share at an exercise price of CAD 0.90 per share. There were no broker warrants issued or commission paid in connection to the offering. All of the securities issued pursuant to the transaction are subject to a statutory hold period of four months and one day from the closing date of the transaction.
お知らせ • Jan 22Canntab Therapeutics Limited Officially Launches its Online E-Commerce PlatformCanntab Therapeutics Limited announced the official launch of its online e-commerce platform. The E-Commerce platform and web site provides Canadians with an opportunity to source true medical THC and CBD in a pharmaceutical grade hard tablet. The Canntab tablet provides patients with many added benefits including ease of use, efficacy, exact dosage, and bioavailability. Canntab is now able to script patients directly online, take in existing or new prescriptions from Doctors or even share a prescription with another LP. Canntab and its patented formulations is the only provider THC and CBD in hard tablet in Canada. Since receiving a Medical Sales License from Health Canada on November 11, 2021, Canntab has been focused on the full commercialization of its brand and products. The recently announced OCS initial shipment and Australian 2nd shipment are just 2 examples of what is expected to be numerous developments in the very near future. In addition, affiliates across Canada like pharmacy groups, health and wellness practitioners, sleep and pain clinics and other medical professionals will now be able to recommend or prescribe product and be compensated for doing so.
Recent Insider Transactions • Oct 03Co-Founder recently bought CA$95k worth of stockOn the 1st of October, Richard Goldstein bought around 135k shares on-market at roughly CA$0.70 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$339k worth in shares.
Recent Insider Transactions Derivative • Jun 11Co-Founder exercised options to buy CA$310k worth of stock.On the 7th of June, Richard Goldstein exercised options to buy 320k shares at a strike price of around CA$0.75, costing a total of CA$240k. This transaction amounted to 65% of their direct individual holding at the time of the trade. Since December 2020, Richard's direct individual holding has increased from 39.19k shares to 464.59k. Company insiders have collectively bought CA$525k more than they sold, via options and on-market transactions, in the last 12 months.
Recent Insider Transactions • May 08Co-Founder recently bought CA$60k worth of stockOn the 5th of May, Richard Goldstein bought around 60k shares on-market at roughly CA$1.00 per share. In the last 3 months, they made an even bigger purchase worth CA$100k. Richard has been a buyer over the last 12 months, purchasing a net total of CA$222k worth in shares.
Recent Insider Transactions • Apr 28Co-Founder recently bought CA$100k worth of stockOn the 23rd of April, Richard Goldstein bought around 100k shares on-market at roughly CA$1.00 per share. This was the largest purchase by an insider in the last 3 months. Richard has been a buyer over the last 12 months, purchasing a net total of CA$162k worth in shares.
お知らせ • Apr 01Canntab Receives Export License Approval from Health CanadaCanntab Therapeutics Limited announced that Health Canada has granted the company an Export License.
お知らせ • Mar 11Canntab Therapeutics Limited Receives $400K Purchase Order in AustraliaCanntab Therapeutics Limited announced that further to an announcement made on October 26, 2020, Canntab has now received an initial purchase order in the amount of $406,200 with its Australian partner, Cann Global Limited of Australia ("Cann Global"). The initial purchase order includes 6 sku's comprised of 2.5mg THC, 5mg THC, 12.5mg CBD, 25mg THC, and combined caplets (a hard coated tablet in the shape of a capsule) with 5mg THC/25mg CBD and 2.5mg THC/12.5mg CBD. Cann Global has already received its import license from the Australian Government Department of Health while Canntab is waiting for an Export License approval from Health Canada to fulfil and ship the order. The products ordered by Cann Global will be distributed throughout Australia to medical distributors, including Doctors, Pharmacies, and Hospitals. Canntab will update its shareholders as soon as its Export License has been approved.
Is New 90 Day High Low • Feb 10New 90-day high: CA$0.95The company is up 36% from its price of CA$0.70 on 11 November 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 92% over the same period.
Is New 90 Day High Low • Dec 09New 90-day high: CA$0.76The company is up 21% from its price of CA$0.63 on 09 September 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 53% over the same period.
お知らせ • Dec 03Canntab Therapeutics Limited Begins Delivery of Tablets to MediPharmCanntab Therapeutics Limited announce that it has completed its first delivery of two (2) of a total of five (5) SKU's ordered by MediPharm Labs Corp. Further to Canntab's announcement dated June 2, 2020, the Company confirms that the total purchase order is approximately $1.3 Million. Canntab intends to complete and deliver the entire order by the end of 2020.
お知らせ • Nov 18Canntab Therapeutics Limited Announces End of Supply and Distribution Agreements with ExactusCanntab Therapeutics Limited announced that Canntab and Exactus, Inc. have blends in hard pill form for therapeutic applications, announces that Canntab and Exactus, Inc. have mutually agreed to terminate the supply and distribution agreements previously announced on November 20, 2019, after determining that the regulatory requirements could not be completed on a timely basis. During a time of pandemic and closed borders, both companies decided it would be best to mutually terminate the agreements in place. However, both companies have expressed an interest in working together in the future, and intend to make a decision in that regard once circumstances surrounding the COVID-19 pandemic have improved.
お知らせ • Nov 07Canntab Therapeutics Limited, Annual General Meeting, Jan 15, 2021Canntab Therapeutics Limited, Annual General Meeting, Jan 15, 2021.
お知らせ • Oct 20Canntab Therapeutics Limited (CNSX:PILL) completed the acquisition of CMAX Assets of CMAX Technologies Inc.Canntab Therapeutics Limited (CNSX:PILL) entered into a binding asset purchase agreement to acquire CMAX Assets of CMAX Technologies Inc. for CAD 1.4 million on August 21, 2020. CMAX Assets includes certain cannabis-processing equipment and leasehold improvements located at 223 Riviera Drive, Markham, Ontario facility. The purchase price will be satisfied through the issuance of 1.9 million common shares. A deposit of 0.2 million Common Shares will be paid to CMAX within 14 days of the execution of the purchase agreement. On July 15, 2020, 200,000 common shares were issued to CMAX as a deposit on this transaction. The transaction is subject to customary closing conditions. The transaction has been approved by the independent Director of Canntab Therapeutics. Canntab Therapeutics Limited (CNSX:PILL) completed the acquisition of CMAX Assets of CMAX Technologies Inc. on October 19, 2020.
お知らせ • Oct 01Canntab Therapeutics Limited Auditor Raises 'Going Concern' DoubtCanntab Therapeutics Limited filed its Annual on Sep 28, 2020 for the period ending May 31, 2020. In this report its auditor, Meyers Norris Penny LLP - MNP LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Reported Earnings • Sep 30Full year earnings released - CA$0.10 loss per shareOver the last 12 months the company has reported total losses of CA$2.61m, with losses widening by 6.0% from the prior year.
お知らせ • Aug 22Canntab Therapeutics Limited (CNSX:PILL) entered into a binding asset purchase agreement to acquire CMAX Assets of CMAX Technologies Inc. for CAD 1.4 million.Canntab Therapeutics Limited (CNSX:PILL) entered into a binding asset purchase agreement to acquire CMAX Assets of CMAX Technologies Inc. for CAD 1.4 million on August 21, 2020. CMAX Assets includes certain cannabis-processing equipment and leasehold improvements located at 223 Riviera Drive, Markham, Ontario facility. The purchase price will be satisfied through the issuance of 1.9 million common shares. A deposit of 0.2 million Common Shares will be paid to CMAX within 14 days of the execution of the purchase agreement. The transaction is subject to customary closing conditions. The transaction has been approved by the independent director of Canntab Therapeutics.
お知らせ • Aug 20Canntab Therapeutics Limited Announces Appointment of Larry Latowsky as CEOCanntab Therapeutics Limited announced that it has appointed Larry Latowsky as CEO effective immediately. Originally appointed as an Advisor to the Company, it was mutually decided that Mr. Latowsky's extensive experience and connections in wholesale, retail and direct to consumer pharmaceutical industries would be an essential ingredient to the operations of the company and accordingly the board of directors decided to appoint Larry as CEO.
